The Study of Hypiran effect on Methamphetamine associated psychosis patients

Phase 4

• Conditions: Methamphetamine associated psychosis.; Mental and behavioural disorders due to use of hallucinogens

• Registration Number: IRCT2016082129447N1
• Lead Sponsor: Iran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: Male
• Target Recruitment: 40

Inclusion Criteria

the patients who are current methamphetamine users have been admitted to the hospital; age between 18 and 70 years old; they have met the criteria for methamphetamine induced psychotic disorder according to DSM-5.
Exclusion criteria: having a diagnosis of bipolar I and II disorder; substance induced mood disorder (with manic symptoms); liver and kidney diseases.

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Glutathione Peroxidase. Timepoint: before intervention, 14 and 28 days after intervention. Method of measurement: colorimetry.;Glutathione Reductase. Timepoint: before intervention, 14 and 28 days after intervention. Method of measurement: colorimetry.;Total Antioxidant Capacity. Timepoint: before intervention, 14 and 28 days after intervention. Method of measurement: colorimetry.;Nitric Oxide. Timepoint: before intervention, 14 and 28 days after intervention. Method of measurement: Elisa.;Malondialdehyde. Timepoint: before intervention, 14 and 28 days after intervention. Method of measurement: Elisa.;Selenoprotein1. Timepoint: before intervention, 14 and 28 days after intervention. Method of measurement: Elisa.;Methamphetamine. Timepoint: 14 after intervention. Method of measurement: HPLC.

Secondary Outcome Measures

Name	Time	Method
BDNF. Timepoint: before intervetion and 28 days after intervention. Method of measurement: ELISA.;VEGF. Timepoint: before intervetion and 28 days after intervention. Method of measurement: ELISA.;DTNBP1. Timepoint: before intervetion and 28 days after intervention. Method of measurement: ELISA.;IL-6. Timepoint: before intervetion and 28 days after intervention. Method of measurement: ELISA.